Navigation Links
New function of gene in promoting cancer found by VCU researchers
Date:11/22/2010

Richmond, Va. (Nov. 22, 2010) Researchers at Virginia Commonwealth University have discovered that a gene well known for its involvement in tumor cell development, growth and metastasis also protects cancer cells from being destroyed by chemotherapy. By inhibiting the expression of this gene, doctors may have a new viable and effective approach for treating aggressive cancers such as breast, liver and prostate carcinomas, malignant gliomas and neuroblastomas that result from high expression of this cancer-promoting gene.

The new study was reported the week of Nov. 22 in PNAS Early Edition, an online publishing of the latest scientific research by the Proceedings of the National Academy of Sciences. The work was a collaboration among researchers from VCU Massey Cancer Center, the VCU Institute of Molecular Medicine (VIMM), and the Department of Human and Molecular Genetics of the VCU School of Medicine, and was led by Paul B. Fisher, M.Ph., Ph.D., Thelma Newmeyer Corman Endowed Chair in Cancer Research at VCU Massey.

The involved gene, AEG-1 (astrocyte elevated gene-1), has been known to directly contribute to cancer cell survival, chemotherapeutic drug resistance and tumor cell progression by regulating diverse intracellular processes. This study reveals for the first time a previously unknown aspect of AEG-1 function by identifying the gene as a potential regulator of protective autophagy, which shields cancer cells from destructive agents and environmental insults and is an important feature that may contribute to AEG-1's tumor-promoting properties. The research further shows that protective autophagy also contributes to AEG-1's chemoresistance properties, and that inhibition of AEG-1 enhances tumor cells' response to chemotherapy.

"Understanding how AEG-1 promotes resistance to chemotherapy and enhances cancer cell survival may lead to treatments that inhibit this gene and its regulated pathways, thereby uncovering potentially new therapeutic targets that can be exploited to enhance the ability of anticancer drugs to fight tumors," said Fisher, who is also chair of VCU's Department of Human and Molecular Genetics and director of VIMM. "The potential for translating these findings into beneficial approaches for patients is major, particularly for patients with aggressive cancers that are difficult to treat because of resistance to current therapies."


'/>"/>

Contact: Jenny Owen
jrowen2@vcu.edu
804-628-2111
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Race Seems to Impact Rate of Kidney Function Decline
2. Noninvasive brain stimulation helps improve motor function in stroke patients
3. Gene Associated With Autism May Alter How Brain Functions
4. Study shows volunteering benefits those with functional limitations
5. Acid reflux, functional dyspepsia have significant impact on disordered sleep
6. Yoga alleviates pain and improves function in fibromyalgia patients
7. Air pollution alters immune function, worsens asthma symptoms
8. Placebo successful in treating women with sexual dysfunction
9. Study identifies underlying dysfunction of seemingly non-critical heart condition
10. Function found for Alzheimers protein
11. Scientists discover the mechanisms and function of a type of mysterious immune cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , ... December 06, 2016 , ... "Add realistic flares ... flicker, flash, and flare from clip to clip with high quality 4K lens flare ... 4K Jewel contains 44 lens flares filmed on the RED Dragon. Utilizing the Dragon ...
(Date:12/5/2016)... , ... December 05, 2016 , ... What: Shriners Hospitals ... the North Pole to our patients – using a video monitor and web-enabled camera. ... hospital will transform the Auditorium into a Christmas Wonderland, which is where the video ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward ... to announce the arrival of the newest Sciton laser in January 2017. The ... use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, ...
(Date:12/5/2016)... ... ... For many years, Andrew G. Zubinas has accumulated over 130 ... the Lithuanian language and its poetry inspired him in writing “ Forest ... all aspects of a living, breathing forest where nothing ever stays the same. His ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted from ... Executive® (ISE®) Central Awards. , Awards include the Information Security Executive® of ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... CRANBURY, N.J. , Dec. 5, 2016 /PRNewswire/ ... pharmaceutical company, today presented data from two Phase ... poster sessions at the 58th annual meeting of ... San Diego, California . The two ... patients with acute myeloid leukemia (AML) and T-cell ...
(Date:12/5/2016)... Dec. 5, 2016   Lexicon Pharmaceuticals, Inc. ... from a Phase 2 clinical study of sotagliflozin, a ... collaboration with JDRF, the leading global organization funding type ... Phase 2 clinical trial, which randomized a total of ... once-daily 400 mg dose of sotagliflozin compared to a ...
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
Breaking Medicine Technology: